Related Experiment Video
Updated: May 12, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
Published on: January 12, 2024
Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice
1Department of Internal Medicine, Korea University Ansan-Hospital, 516 Kojan-Dong, Ansan City, Kyungki-Do, 425-020, Korea.
Abstract:
Chronic inflammation caused by high glucose and high free fatty acid (FFA) concentrations is a major contributor to the pathogenesis of type 2 diabetes. Recent evidence suggests that activation of Toll-like receptor (TLR) signaling induces peripheral insulin resistance and mediates central insulin and leptin resistance. In this study, we investigated the renal effects of TLR4 signaling blockade in type 2 diabetic mice. Eight-week-old db/db mice were treated for 12 weeks with (S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid (GIT27), which targets macrophages through the inhibition of TLR4- and TLR2/6-mediated signaling pathways. Although GIT27 treatment improved glycemic control and insulin tolerance, which is associated with a lower lipid profile, it did not impact body weight or food consumption. GIT27 treatment also markedly decreased urinary albumin excretion, decreased proinflammatory cytokine synthesis, improved tissue lipid metabolism, induced oxidative stress, and improved glomerulosclerosis compared with the control db/db group. In cultured podocytes and adipocytes, high glucose levels with FFA stimulation increased TLR4 expression and proinflammatory cytokine synthesis, but the effects were abolished by GIT27 treatment. In addition, knockdown of TLR4 expression by stealth small interfering RNA abolished FFA-induced proinflammatory cytokine synthesis in cultured podocytes. In conclusion, our results suggest that GIT27 treatment improves insulin resistance and protects against the renal injury that occurs in type 2 diabetic nephropathy through both metabolic and antiglomerulosclerotic mechanisms. These results suggest that TLR pathway inhibition might play a direct protective role in diabetic kidney disease.
Insights
Blocking Toll-like receptor 4 (TLR4) signaling with GIT27 improved glycemic control and protected against kidney damage in type 2 diabetes. This suggests TLR pathway inhibition is a promising therapeutic strategy for diabetic kidney disease.
Area of Science:
- Immunology
- Metabolic disorders
- Nephrology
Background:
- Chronic inflammation from high glucose and free fatty acids (FFAs) drives type 2 diabetes pathogenesis.
- Toll-like receptor (TLR) signaling activation contributes to insulin resistance and leptin resistance.
Purpose of the Study:
- To investigate the renal protective effects of TLR4 signaling blockade in a mouse model of type 2 diabetes.
- To evaluate the impact of GIT27, a TLR4 signaling inhibitor, on metabolic and renal parameters.
Main Methods:
- Eight-week-old db/db mice were treated with GIT27 for 12 weeks.
- Assessed glycemic control, insulin tolerance, lipid profile, body weight, food consumption, urinary albumin excretion, and renal histopathology.
- Investigated TLR4 expression and cytokine synthesis in cultured podocytes and adipocytes.
Main Results:
- GIT27 treatment improved glycemic control, insulin tolerance, and lipid profiles without affecting body weight or food intake.
- Markedly reduced urinary albumin excretion, proinflammatory cytokine synthesis, and glomerulosclerosis.
- In vitro studies showed GIT27 abolished high glucose/FFA-induced TLR4 expression and cytokine production in podocytes and adipocytes.
Conclusions:
- GIT27 treatment ameliorates insulin resistance and protects against renal injury in type 2 diabetic nephropathy via metabolic and anti-glomerulosclerotic mechanisms.
- TLR pathway inhibition demonstrates potential as a direct protective strategy for diabetic kidney disease.
Related Concept Videos
Type II Diabetes II: Pathophysiology
Diabetic Retinopathy
Type I Diabetes II: Pathophysiology
Diabetic Neuropathy
Diabetic Nephropathy

